This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
DBN1 / Drebrin · IHC design guide
Design Immunohistochemistry for DBN1
Plan DBN1 chromogenic IHC in paraffin sections using strongly stained cerebellar processes as a positive reference (HPA tissue IHC). Assess cytoplasmic and membranous staining (HPA tissue IHC) with consistent fixation across samples.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
DBN1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and membranous tissue staining (HPA tissue IHC) | |
| Staining pattern | High cerebellar process signal; cytoplasmic/membranous overall (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A05530-1) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep paraffin-section fixation consistent across samples. (standard IHC practice; not target-specific) | |
| Caveat | Hippocampal neurons stain weakly as a positive control (HPA tissue IHC) | |
| Regulation | Expression regulation is not reported (UniProt) | |
| Isoform / epitope | 3 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended DBN1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is followed by published DBN1 staining conditions from three PMC articles (datasheet; PMC6456690; PMC12262305; PMC7352383).
| Sample | Paraffin-embedded human laryngeal carcinoma tissue; fixative not specified (datasheet A05530-1) |
| Fixation | Image fixative and duration unreported (datasheet A05530-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A05530-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A05530-1) |
| Primary antibody | Rabbit anti-DBN1, 2-5 μg/ml (datasheet A05530-1) |
| Primary incubation | Overnight at 4 °C (datasheet A05530-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A05530-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | DBN1-positive staining in processes in granular layer of cerebellum (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and membranous expression in several tissues, most abundant in CNS. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet). Sodium citrate retrieval is a published alternative (PMC6456690).
Section 2
What Is the Expected DBN1 Staining Pattern?
DBN1 staining is expected in the cytoplasm, cell cortex and projections, with membranous staining in some tissues (UniProt Q16643 subcellular location; HPA tissue IHC). Cerebellar granular-layer processes and testicular spermatogonia provide high-staining examples; cortical neuropil shows medium staining (HPA tissue IHC). HPA rates the tissue pattern Enhanced, citing consistency between antibody staining and RNA expression (HPA tissue IHC reliability). DBN1 has no transmembrane segment, so a membrane-associated pattern does not imply a membrane-spanning protein (UniProt Q16643 topology).
| Strong staining outlines processes in the cerebellar granular layer; cortical neuropil stains more moderately (HPA tissue IHC). | This supports the expected process-rich CNS pattern. Assess the stained structures as well as intensity: HPA reports High in cerebellar processes and Medium in cortical neuropil, while UniProt places DBN1 in dendrites and the cell cortex (HPA tissue IHC; UniProt Q16643 subcellular location). |
| Cytoplasmic or peripheral staining appears in spermatogonia, stromal cells or glandular cells (HPA tissue IHC). | Interpret intensity against the named cell population: spermatogonia are High, endometrial stromal cells and epididymal or gallbladder glandular cells are Medium (HPA tissue IHC). Cytoplasmic and membranous expression across several tissues is compatible with the HPA profile (HPA tissue IHC). |
| Predominantly nuclear staining appears without convincing cytoplasmic, peripheral or process staining. | Treat this as an unexpected compartment pattern requiring review, because UniProt lists cytoplasm, cell cortex, junctions and projections, while HPA describes cytoplasmic and membranous tissue staining (UniProt Q16643 subcellular location; HPA tissue IHC). Compare a known-positive section and detection controls before assigning it to DBN1 (general IHC practice). |
| Strong staining appears in adipocytes or cardiomyocytes, which HPA records as Not detected (HPA tissue IHC). | Check whether the signal follows the named cells or surrounding structures. Persistent cell-associated staining raises cross-reactivity or endogenous detection activity as possibilities (general IHC practice); HPA's Not detected calls apply to those specific cell types, not every cell in the tissue (HPA tissue IHC). |
| No signal appears in cerebellar granular-layer processes or testicular spermatogonia. | A blank known-positive population makes the run difficult to interpret: both populations are High in HPA tissue IHC (HPA tissue IHC). Check section quality, retrieval, antibody application and detection with appropriate controls (general IHC practice) before treating another tissue as DBN1-negative. |
💡Expected DBN1 appearanceA convincing positive shows High process staining in the cerebellar granular layer or High spermatogonial staining, with cytoplasmic or peripheral localisation; isolated nuclear staining or strong staining in HPA Not detected cell populations warrants investigation (HPA tissue IHC; UniProt Q16643 subcellular location).
| Anatomical and cell-type context | HPA reports abundant CNS staining but different levels by structure: cerebellar granular-layer processes are High, cortical neuropil is Medium, and hippocampal neuronal cells are Low (HPA tissue IHC). UniProt documents expression in specific hippocampal layers and pyramidal-cell regions; that record does not assign those structures a uniform IHC intensity (UniProt Q16643 tissue specificity). |
| Peripheral versus cytoplasmic signal | DBN1 is an actin cytoskeleton-organizing protein associated with projections, the cortex and junctions (UniProt Q16643 function and subcellular location). HPA describes cytoplasmic and membranous tissue staining (HPA tissue IHC). With no transmembrane segment, a peripheral signal should be read as localisation, not evidence of membrane-spanning topology (UniProt Q16643 topology). |
| Antibody validation and scope | HPA lists 2 rabbit polyclonal antibodies, HPA051452 and HPA056940, with Enhanced IHC status (HPA antibodies). That supports the reported tissue pattern; it does not establish that every chromogenic protocol, section or unexpected stained cell will perform alike (HPA antibodies; general IHC practice). |
| Isoforms and epitope information | UniProt lists 3 DBN1 isoforms (UniProt Q16643 isoforms). No antibody epitope or isoform coverage is supplied here, so an apparent difference between sections cannot be assigned to a particular isoform from this evidence alone (UniProt Q16643 isoforms; supplied antibody record). |
| IF/ICC Q&A | Q: Should IF/ICC show the same pattern as tissue IHC? A: HPA places the main ICC-IF signal at the plasma membrane, with additional actin-filament localisation, in its imaged cell lines (HPA subcellular ICC-IF). Treat that as cell-culture localisation evidence; tissue intensity and cell-type expectations come from HPA tissue IHC. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive cerebellar processes show little or no chromogenic signal (HPA tissue IHC). | The expected High population is missing; a failed run or unsuitable section is possible (HPA tissue IHC; general IHC practice). | Inspect tissue preservation and compare a positive-control section; verify retrieval, primary-antibody application and the detection reagents before interpreting low-staining samples (general IHC practice). No DBN1-specific retrieval condition is supplied. |
| Brown precipitate covers many compartments or extends beyond cell boundaries. | Diffuse background can arise from incomplete blocking, excess antibody or insufficient washing (general IHC practice); it cannot be assigned to DBN1 localisation from appearance alone. | Review the no-primary control, blocking and washes; adjust antibody concentration within a validated workflow, then reassess whether the signal follows HPA-described cells and structures (general IHC practice; HPA tissue IHC). |
| A strong, predominantly nuclear pattern replaces cytoplasmic or process staining. | That compartment is outside the listed DBN1 locations and HPA tissue profile (UniProt Q16643 subcellular location; HPA tissue IHC). | Compare with a known-positive section and a no-primary control; confirm that the cytoplasmic or peripheral signal is reproducible before scoring nuclear staining as specific (general IHC practice; HPA tissue IHC). |
| Adipocytes, cardiomyocytes or adrenal glandular cells stain strongly despite HPA Not detected calls (HPA tissue IHC). | Cross-reactivity or endogenous detection activity may explain unexpected cell-associated chromogen (general IHC practice); an HPA call concerns the specified cell population (HPA tissue IHC). | Check no-primary and detection controls, inspect which cells contain signal, and compare staining with an HPA High population in the same run (general IHC practice; HPA tissue IHC). |
| Hippocampal neuronal cells look weak beside strongly stained cerebellar processes. | This contrast can match HPA's Low hippocampal neuronal-cell and High cerebellar-process calls (HPA tissue IHC). UniProt's hippocampal expression record does not require equal IHC intensity (UniProt Q16643 tissue specificity). | Score each anatomical population separately, using its own expected HPA level; avoid calling the run failed solely because hippocampal neuronal staining is weak (HPA tissue IHC). |
| A peripheral rim is interpreted as proof that DBN1 spans the plasma membrane. | UniProt lists no transmembrane segment, despite peripheral and junctional localisation (UniProt Q16643 topology and subcellular location). | Report the observed cytoplasmic or membranous staining pattern without inferring membrane-spanning topology; use the named positive cell population and compartment to support the IHC interpretation (HPA tissue IHC; UniProt Q16643 topology). |
Experiment evidence
IHC & IF images showing DBN1 staining
A05530-1 · IHCIHC analysis of Drebrin/DBN1 using anti-Drebrin/DBN1 antibody (A05530-1). Drebrin/DBN1 was detected in a paraffin-embedded section of human
A05530-1 · IHCIHC analysis of Drebrin/DBN1 using anti-Drebrin/DBN1 antibody (A05530-1). Drebrin/DBN1 was detected in a paraffin-embedded section of human
A05530-1 · IFIF analysis of Drebrin/DBN1 using anti-Drebrin/DBN1 antibody (A05530-1). Drebrin/DBN1 was detected in an immunocytochemical section of CACO-
M05530-4 · IHCIHC analysis of DBN1 using anti-DBN1 antibody (M05530-4). DBN1 was detected in a paraffin-embedded section of human ovarian serous carcinoma
M05530-4 · IHCIHC analysis of DBN1 using anti-DBN1 antibody (M05530-4). DBN1 was detected in a paraffin-embedded section of human thyroid cancer tissue. H
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000113758-DBN1/tissue/cerebral+cortex#imid_16022339
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000113758-DBN1/tissue/colon#imid_16022265
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000113758-DBN1/tissue/liver#imid_16022274
HPA · GallbladderHuman Protein Atlas IHC, Gallbladder. Source: https://www.proteinatlas.org/ENSG00000113758-DBN1/tissue/gallbladder#imid_16022250
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA051452; green = DBN1, blue = nucleus, red = microtubules.
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA051452; green = DBN1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for DBN1 IHC & IF
🧪Run cerebellum first; processes in its granular layer should stain (HPA: High in processes in granular layer). Use adipose tissue as the negative tissue, assessing adipocytes (HPA: Not detected in adipocytes); on the cerebellum slide, nuclei and areas outside the stained processes should provide internal background for comparison (UniProt Q16643 subcellular localization).
Positive control tissue: Cerebellum (Processes in granular layer, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show DBN1 in HeLa, PC-3, U2OS, KOLF2.1J, with annotated localisation: Plasma membrane (approved) (HPA subcellular).
Technical controls: Include no-primary (secondary-only), a concentration-matched rabbit IgG control matched to the primary antibody’s clonality, and DBN1-knockout tissue or a peptide-block control if available (selected-SKU caption: rabbit primary antibody). For cerebellum, block endogenous peroxidase and check for endogenous biotin background because the documented IHC detection uses a biotinylated secondary, streptavidin–biotin complex and DAB (selected-SKU tissue-IHC caption).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the exact A05530-1 tissue-IHC caption leaves the fixative unreported; its paraffin-section example uses heat retrieval in EDTA at pH 8.0, so retrieval should be checked during setup (selected-SKU tissue-IHC caption). Paraffin IHC has a documented example, while the supplied evidence does not establish whether frozen sections or IF would be easier (selected-SKU tissue-IHC caption; HPA subcellular ICC-IF images). In cerebellum, score the granular-layer processes against nearby background so dense process staining is not mistaken for staining of every cell (HPA: High in processes in granular layer).
HPA tissue IHC evidence for DBN1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Processes in granular layer | High | Protein (IHC) | HPA → |
| Testis | Spermatogonia cells | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuropil | Medium | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | Medium | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Endocrine cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced DBN1 IHC Tips
Troubleshoot DBN1 staining in paraffin sections by checking retrieval, cellular pattern, controls, and scoring before interpreting differences between samples.
Which retrieval conditions should I start with for DBN1 in paraffin sections?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A05530-1). The selected image used this retrieval before overnight incubation at 4°C with 2 μg/ml primary antibody, so reproduce those conditions when assessing a weak stain (datasheet A05530-1). If signal remains weak, compare a second retrieval condition on adjacent sections while holding antibody concentration, detection chemistry, and imaging constant; treat that condition as an optimization experiment. Check a positive control showing DBN1-rich processes in the cerebellar granular layer before calling a specimen negative (HPA: High in cerebellar granular-layer processes).
How should I troubleshoot possible fixation effects on DBN1 staining?
Target-specific sensitivity of DBN1 to fixation is unknown from the supplied evidence; the selected paraffin-section caption does not state a fixative (datasheet A05530-1). Record the actual fixative and fixation interval for every specimen, then compare sections processed together with the same EDTA pH 8.0 retrieval and detection settings (datasheet A05530-1: retrieval). Use a concurrently stained positive-control section to distinguish a specimen-wide staining failure from a difference in DBN1 expression; cerebellar granular-layer processes are one documented positive pattern (HPA: High). If morphology is damaged or signal varies across a section, review tissue processing and section quality before assigning a biological interpretation.
What DBN1 staining pattern should I expect in tissue sections?
Assess DBN1 in cytoplasm, cell cortex, projections, and junction-associated regions, consistent with its annotated locations (UniProt Q16643: subcellular location). In neural tissue, inspect processes and neuropil rather than scoring only neuronal cell bodies; cerebellar granular-layer processes are High and cerebral-cortex neuropil is Medium in the tissue atlas (HPA: tissue IHC). Membrane-adjacent staining can also be plausible because cell imaging places DBN1 mainly at the plasma membrane with additional actin-filament localization (HPA: subcellular). Use morphology and a counterstain to assign signal to cells or processes, and compare compartments on adjacent sections before calling diffuse chromogen specific.
Could isoforms or epitope accessibility explain inconsistent DBN1 staining?
DBN1 has 3 annotated isoforms and an ADF-H domain at residues 3–134, so the antibody's recognized epitope matters when comparing patterns (UniProt Q16643: isoforms, domains). The supplied caption does not identify the A05530-1 epitope or establish which isoforms it detects (datasheet A05530-1: selected IHC caption). Ask for epitope mapping or isoform-reactivity information before attributing a staining difference to alternative splicing. DBN1 also has annotated phosphorylation sites, including Ser141 and Thr331, but their effect on this antibody's paraffin-section staining is unreported (UniProt Q16643: modified residues).
How can I check an unexpected IHC pattern with multiplex immunofluorescence?
Use the separate IF/ICC workflow to pair DBN1 with a validated marker for the expected cell type, then check whether the signals occupy the same cells and appropriate compartments. Choose a DBN1 fluorophore in a channel with low measured tissue autofluorescence, include single-label controls, and set exposures before comparing samples. Because DBN1 lacks a transmembrane segment and occupies cytoplasmic and cortical compartments, test permeabilisation when the antibody must reach an intracellular epitope; its exact epitope is not given (UniProt Q16643: topology, subcellular location; datasheet A05530-1: selected caption). Compare the IF pattern with chromogenic IHC cautiously because the supplied IHC caption does not specify its fixative (datasheet A05530-1).
How do I separate DBN1 staining from chromogenic background?
Run a no-primary control through the same secondary antibody and DAB development steps, and include a peroxidase block in the general chromogenic workflow. The selected image used a biotinylated goat anti-rabbit secondary, streptavidin–biotin detection, and DAB, so evaluate diffuse deposits against that detection setup (datasheet A05530-1). Titrate primary antibody around the caption's 2 μg/ml condition and compare matched sections when background obscures cellular detail (datasheet A05530-1). Favor interpretable cytoplasmic or process-associated staining over pigment, tissue-edge deposits, or necrotic areas; those expected compartments follow DBN1 localization (UniProt Q16643: subcellular location).
What should I measure when comparing DBN1 across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the compartment and cell population before scoring: DBN1 may occur in processes, cytoplasm, and membrane-adjacent regions (UniProt Q16643: subcellular location; HPA: tissue IHC profile). For cell-rich regions, report percent positive cells and an H-score from 0–300, using the same intensity thresholds and counterstain review across specimens. For process-rich regions, measure positive area or process density per mm² within a consistent annotated region; cerebellar granular-layer processes and cortical neuropil illustrate relevant compartments (HPA: tissue IHC). Normalize to viable tissue area or the number of eligible cells, and exclude folds, necrosis, and poorly preserved edges before comparing groups.
When is an apparent DBN1-positive result likely to be artefactual?
A credible result follows cell and compartment morphology: DBN1 is annotated in cytoplasm, projections, cortex, and junctions, while tissue IHC highlights neural processes and several non-neural cell populations (UniProt Q16643: subcellular location; HPA: tissue IHC). Question signal confined to nuclei, necrotic debris, or tissue edges when the expected cellular pattern is absent. Compare a no-primary control and review the peroxidase block if brown deposits persist, because the selected chromogenic method develops with DAB (datasheet A05530-1). Interpret a positive cell only in its tissue context: the atlas reports High staining in spermatogonia but no detection in adipocytes (HPA: tissue IHC).
Boster reagents
Best DBN1 / Drebrin IHC Antibodies
Two antibodies have paraffin-section IHC images from human tissues, and one also has ICC/IF imagery from CACO-2 cells (catalog image captions).
Real IHC data
Anti-Drebrin/DBN1 Antibody ®
Cat # A05530-1
Real IHC data
Anti-Drebrin/DBN1 Antibody ® (monoclonal, 4F6E7)
Cat # M05530-4
A05530-1 has IHC images from human laryngeal carcinoma, lung cancer, thyroid papillary carcinoma, and cerebellum, plus an ICC/IF image from CACO-2 cells (catalog image captions). M05530-4 has IHC images from human ovarian serous carcinoma, human thyroid cancer, and rat brain (catalog IHC image captions).
Which to pick: For paraffin-section IHC, choose A05530-1 for its human tissue examples (A05530-1 IHC image captions), or M05530-4 for its monoclonal clone 4F6E7 and human and rat tissue examples (catalog clone field; M05530-4 IHC image captions). For IF/ICC, choose A05530-1: both applications are listed and its CACO-2 image documents ICC/IF staining (A05530-1 applications; A05530-1 IF image caption). For mouse-reactive tissue IHC, M05530-4 lists mouse reactivity, although its IHC images show only human and rat sections; the fixative is unreported for both antibodies’ paraffin-section images (M05530-4 reactivity; catalog IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q16643 (DREB_HUMAN, Drebrin).
- Human Protein Atlas. DBN1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. DBN1 subcellular location (ICC-IF): Mainly localized to the plasma membrane. In addition localized to the actin filaments..
- Human Protein Atlas. DBN1 antibody validation summary (2 antibodies).
- Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration. Frontiers in neuroscience 2019 — PMC6456690.
- Integrated Spatial Analysis of Ovarian Precancerous Lesions. bioRxiv : the preprint server for biology 2025 — PMC12262305.
- Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. Cancers 2020 — PMC7352383.
- Gut microbiota of the young ameliorates physical fitness of the aged in mice. Microbiome 2022 — PMC9791737.
- PubMed PMID:8216329 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:17974005 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for DBN1 (Drebrin). Expected localisation Cytoplasmic and membranous tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A05530-1). Validated IHC antibody: A05530-1 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Processes in granular layer); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human laryngeal carcinoma tissue; fixative not specified (datasheet A05530-1); 2. Fixation: Image fixative and duration unreported (datasheet A05530-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A05530-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A05530-1); 8. Primary antibody: Rabbit anti-DBN1, 2-5 μg/ml (datasheet A05530-1); 9. Primary incubation: Overnight at 4 °C (datasheet A05530-1). Watch for: Fixation: Keep paraffin-section fixation consistent across samples. (standard IHC practice; not target-specific); Caveat: Hippocampal neurons stain weakly as a positive control (HPA tissue IHC); Isoform / epitope: 3 isoforms; epitope coverage is unspecified (UniProt); Regulation: Expression regulation is not reported (UniProt). Evidence: UniProt Q16643, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the plasma membrane. In addition localized to…, Datasheet A05530-1, PMC6456690, PMC12262305. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/DBN1/immunohistochemistry-ihc-guide.